SMS Pharmaceuticals LtdQ2 FY22Pharmaceuticals & Biotechnology

SMS Pharmaceuticals Ltd

Q2 FY22 Earnings Call Analysis

Management growth scorecard

Revenue

Category 2

Margin

Category 3

Fundraise

N/A

Order

N/A

Capex

Yes

1 of 3 growth signals are positive — mixed outlook.

Revenue guidance

Category 2

→Ibuprofen is a flagship product with recent CEP approval, enabling sales in European markets and expected to generate good revenues going forward.
→Targeting 30-35% growth in Ibuprofen contribution.
→Plans to add 8 to 10 new products to the portfolio in the next year to increase non-ARV product revenue share.
→Sitagliptin launch is recent; Indian market estimated around 150+ tons, offering significant opportunity.
→The company is focused on expanding market share domestically and internationally, especially for newly launched products.
→ARV product Tenofovir contributes around 35% of revenue; sales depend on tender outcomes with some growth potential.
→Joint Venture (JV) products could contribute 20-25% of revenue, up from around 15%.
→Overall, non-ARV products are positioned for significant growth to diversify revenue and reduce dependence on ARV APIs.
→FY23 is expected to see improved capacity utilization and sales volumes, with EBITDA and PAT positive turnaround targeted.

Category 3

→The company is optimistic about turning EBITDA positive by end of Q2 FY23 and PAT positive by end of FY23 (Page 12).
→Strong focus on commercializing Ibuprofen in Europe after CEP approval, targeting significant revenue growth (Pages 6, 13).
→Ibuprofen revenue contribution could grow to 35-40% of the top line by FY23-24 (Page 6).
→Growth expected from newly launched products such as Sitagliptin with an India market size assumption of around 150 tons and targeting good market share (Pages 14-15).
→ARV product Tenofovir sales remain uncertain due to tender dependencies; company working to diversify product mix to reduce dependence on ARV (Pages 12, 15).
→Launches from JV expected to contribute 20-25% of revenue, with focus on new products post-patent expiry (Page 8).
→R&D expenses expected to increase by about 20% in FY23, supporting new product launches (Page 4).
→Overall, the company is confident of overcoming short-term challenges and plans steady revenue and profitability growth through new product launches, customer additions, and geographical expansion (Pages 3-4).

Get access to all 5 sections — revenue, margin, fundraise, orderbook, and capex — for SMS Pharmaceuticals Ltd and 1,400+ other companies.

→The transcript does not mention any current or planned fundraising through debt or equity.
→There is no discussion of any capital raising activities in the Q1 FY23 earnings call held on August 18, 2022.
→The management focuses on commercial expansion, product launches, and improving profitability without mentioning any new funding rounds.
→Capex and R&D investments are being managed internally without indication of external fundraising.
→Hence, based on available information, no new debt or equity fundraising is planned or announced as of this call.

→The company is currently facing difficulty in predicting orderbook due to delays and uncertainty in government tenders, especially in the ARV segment.
→Clarity on ARV orders and tender outcomes is expected by the next quarter.
→Inventory buildup (approx. ₹275 crore) is partly due to readiness for product launches like Sitagliptin and Molnupiravir.
→The company is actively pushing partners for demand forecasts and contract manufacturing projections.
→Ibuprofen and other products are gaining traction, with aims to increase capacity utilization from 22% in Q1 to 70-80% by Q4 FY23.
→New product launches (including Sitagliptin in India) provide significant revenue potential and order flow opportunities.
→The business is focused on diversifying revenue streams beyond ARV products and expanding into domestic and international markets.

Yes

→No explicit mention of new or upcoming CAPEX or capital investments in the transcript.
→CFO Vamsi Krishna Potluri noted that depreciation remained nominal in FY23, as major capitalization happened in FY22, indicating limited new CAPEX in the current fiscal year.
→The company is focusing on commercializing new products (e.g., Sitagliptin, Ibuprofen) and expanding R&D (planned growth of 20% in R&D spend in FY23).
→Emphasis placed on strategic investments in product launches, geographic expansion, and customer addition rather than heavy capital expenditure.
→Inventory build-up was noted for launching Sitagliptin and COVID-related drugs, but raw material purchases and major CAPEX are under control.
→Overall, strategic focus is on operational expansion rather than announced large-scale capital investments at this time.

How does SMS Pharmaceuticals Ltd rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature

1SMS Pharmaceuticals Ltd

Rev 2Mar 3

See full Pharmaceuticals & Biotechnology sector rankings

Want more stocks like SMS Pharmaceuticals Ltd?

Build an AI portfolio filtered by sector, market cap, and growth rank. Takes 2 minutes.